209 related articles for article (PubMed ID: 28632502)
1. Targeting activated protein C to treat hemophilia.
Polderdijk SGI; Baglin TP; Huntington JA
Curr Opin Hematol; 2017 Sep; 24(5):446-452. PubMed ID: 28632502
[TBL] [Abstract][Full Text] [Related]
2. Design and characterization of an APC-specific serpin for the treatment of hemophilia.
Polderdijk SG; Adams TE; Ivanciu L; Camire RM; Baglin TP; Huntington JA
Blood; 2017 Jan; 129(1):105-113. PubMed ID: 27789479
[TBL] [Abstract][Full Text] [Related]
3. Serpins, New Therapeutic Targets for Hemophilia.
Aymonnier K; Kawecki C; Arocas V; Boulaftali Y; Bouton MC
Thromb Haemost; 2021 Mar; 121(3):261-269. PubMed ID: 32987444
[TBL] [Abstract][Full Text] [Related]
4. Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C.
Jiang M; Yang F; Jiang Y; Cheng L; Han J; Yi J; Zhang G; Ma Z; Cao L; Zuo B; Zhou L; Huang L; Niu S; Xia Z; Zhou X; Bai X; Esmon NL; Ruan C; Xia L; Han Y; Esmon CT; Wu D; Xu J
Blood Adv; 2022 Jun; 6(11):3304-3314. PubMed ID: 35390147
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of activated protein C anticoagulant activity protects against hemophilic arthropathy in mice.
Magisetty J; Kondreddy V; Keshava S; Das K; Esmon CT; Pendurthi UR; Rao LVM
Blood; 2022 May; 139(18):2830-2841. PubMed ID: 35143636
[TBL] [Abstract][Full Text] [Related]
6. Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia.
Zhao XY; Wilmen A; Wang D; Wang X; Bauzon M; Kim JY; Linden L; Li L; Egner U; Marquardt T; Moosmayer D; Tebbe J; Glück JM; Ellinger P; McLean K; Yuan S; Yegneswaran S; Jiang X; Evans V; Gu JM; Schneider D; Zhu Y; Xu Y; Mallari C; Hesslein A; Wang Y; Schmidt N; Gutberlet K; Ruehl-Fehlert C; Freyberger A; Hermiston T; Patel C; Sim D; Mosnier LO; Laux V
Nat Commun; 2020 Jun; 11(1):2992. PubMed ID: 32532974
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models.
Jiang M; Yang F; Jiang Y; Cheng L; Han J; Yi J; Zuo B; Huang L; Ma Z; Li T; Cao LJ; Xia Z; Bai X; Jia C; Yang TTC; Esmon NL; Ruan C; Xia L; Esmon CT; Han Y; Wu D; Xu J
Blood; 2023 Sep; 142(12):1071-1081. PubMed ID: 37294924
[TBL] [Abstract][Full Text] [Related]
8. Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
Girard TJ; Lasky NM; Grunz K; Broze GJ
J Thromb Haemost; 2019 Jan; 17(1):149-156. PubMed ID: 30451376
[TBL] [Abstract][Full Text] [Related]
9. Engineering a protein Z-dependent protease inhibitor (ZPI) mutant as a novel antagonist of ZPI anticoagulant function for hemophilia treatment.
Huang X
J Thromb Haemost; 2019 Oct; 17(10):1655-1660. PubMed ID: 31423718
[TBL] [Abstract][Full Text] [Related]
10. Peptidomimetic inhibitors for activated protein C: implications for hemophilia management.
Butenas S; Orfeo T; Kalafatis M; Mann KG
J Thromb Haemost; 2006 Nov; 4(11):2411-6. PubMed ID: 17059471
[TBL] [Abstract][Full Text] [Related]
11. An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C.
von Drygalski A; Bhat V; Gale AJ; Burnier L; Cramer TJ; Griffin JH; Mosnier LO
PLoS One; 2014; 9(8):e104304. PubMed ID: 25127130
[TBL] [Abstract][Full Text] [Related]
12. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions.
Mosnier LO; Yang XV; Griffin JH
J Biol Chem; 2007 Nov; 282(45):33022-33. PubMed ID: 17872949
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders.
De Nanteuil G; Gloanec P; Béguin S; Giesen PL; Hemker HC; Mennecier P; Rupin A; Verbeuren TJ
J Med Chem; 2006 Aug; 49(17):5047-50. PubMed ID: 16913694
[TBL] [Abstract][Full Text] [Related]
14. Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant.
von Drygalski A; Cramer TJ; Bhat V; Griffin JH; Gale AJ; Mosnier LO
J Thromb Haemost; 2014; 12(3):363-72. PubMed ID: 24818532
[TBL] [Abstract][Full Text] [Related]
15. Activated protein C protects against renal ischaemia/reperfusion injury, independent of its anticoagulant properties.
Lattenist L; Jansen MP; Teske G; Claessen N; Meijers JC; Rezaie AR; Esmon CT; Florquin S; Roelofs JJ
Thromb Haemost; 2016 Jul; 116(1):124-33. PubMed ID: 27052416
[TBL] [Abstract][Full Text] [Related]
16. Activated protein C has a regulatory role in factor VIII function.
Wilhelm AR; Parsons NA; Samelson-Jones BJ; Davidson RJ; Esmon CT; Camire RM; George LA
Blood; 2021 May; 137(18):2532-2543. PubMed ID: 33512448
[TBL] [Abstract][Full Text] [Related]
17. Novel treatments for hemophilia through rebalancing of the coagulation cascade.
Zhao Y; Weyand AC; Shavit JA
Pediatr Blood Cancer; 2021 May; 68(5):e28934. PubMed ID: 33577709
[TBL] [Abstract][Full Text] [Related]
18. An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor.
Müller J; Isermann B; Dücker C; Salehi M; Meyer M; Friedrich M; Madhusudhan T; Oldenburg J; Mayer G; Pötzsch B
Chem Biol; 2009 Apr; 16(4):442-51. PubMed ID: 19389630
[TBL] [Abstract][Full Text] [Related]
19. Identification of serpins specific for activated protein C using a lysate-based screening assay.
Polderdijk SGI; Huntington JA
Sci Rep; 2018 Jun; 8(1):8793. PubMed ID: 29884816
[TBL] [Abstract][Full Text] [Related]
20. A novel protein C-factor VII chimera provides new insights into the structural requirements for cytoprotective protease-activated receptor 1 signaling.
Gleeson EM; McDonnell CJ; Soule EE; Willis Fox O; Rushe H; Rehill A; Smith OP; O'Donnell JS; Preston RJS
J Thromb Haemost; 2017 Nov; 15(11):2198-2207. PubMed ID: 28834159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
